Abstract Library

#3049 Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis

Introduction: A paucity of in vitro and in vivo models has limited the study of Neuroendocrine neoplasms (NENs). Moreover, little is known about normal neuroendocrine (NE) cells and how they contribute to NEN formation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dayton T, Den Hartigh L, Levy S, van den Berg J, Kok N,

Keywords: Organoids, NENs, pulmonary neuroendocrine cells,

#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening

Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Kaemmer C, Ellen A,

Keywords: SBNET, drug screening, spheroids, PDX models, precision medicine,

#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents

Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Grötzinger C, Exner S, Sedding D, Baum R,

Keywords: peptide radioreceptor therapy, Lu-177-DOTATOC, PRRT, bortezomib, in vivo model, SPECT/CT Imaging, chicken CAM model, Sensitizer, DNA damage repair,

#2181 Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth

Introduction: Neuroendocrine tumors (NETs) are a genetically diverse set of rare tumors, which have limited treatment options. The development of more effective therapies for NETs has been limited in part by the absence of in vitro and in vivo models that accurately represent the heterogeneity of these tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dayton T

Authors: Dayton T, Beumer J, Den Hartigh L, Leewaarde R, Van den Berg J,

Keywords: Organoids, neuroendocrine tumors,

#1180 A Novel Human Cell Line from Familial Medullary Thyroid Carcinoma

Introduction: Cell lines from hereditary medullary thyroid carcinomas (MTC) are very rare, therefore, there is a substantial need to establish new cell lines. Here, we present a novel familial MTC (FMTC) cell line, designated SCHWE.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Pfragner R, Schwach G, Hoeger H, Ghaffari Tabrizi-Wizsy N, Tam Amersdorfer C,

Keywords: novel MTC cell line, familial MTC, xenografts,